Introduction
Despite a remarkable understanding of molecular and cellular defects responsible for ␤-thalassemia, there is still no safe and specific therapy for the human disease. The availability of natural 1, 2 and knock-out mouse models 3, 4 for this pathology is helpful in devising therapeutic approaches, especially in reducing the amount of membrane-bound ␣ globin chain and the ␣/non-␣ globin chain imbalance as well as increasing fetal or similar hemoglobin.
5,6
The natural mouse ␤-thalassemic model (Hbb thal 1) used in this present study is a consequence of the deletion of the ␤ major globin gene 2 . Homozygous ␤-thalassemic mice have clinical and erythrocyte features similar to those observed in human ␤-thalassemia intermedia: 7, 8 hypochronic anemia, splenomegaly, unpaired and insoluble ␣ hemoglobin chains and membrane protein alterations. The absence of the ␤ major globin chain is incompletely compensated for by an increase in the ␤ minor chain synthesis. 9 Several studies indicate that the ␤ minor globin expression has features of fetal hemoglobin (HbF) synthesis in humans. The ␤ minor globin chain synthesis declines during ontogeny and increases under conditions that are associated with enhanced HbF synthesis in humans: erythropoietic stress, 10 11 and ␤-thalassemia. 9 Moreover, ␤ minor globin chain expression has been shown to increase in response to recombinant erythropoietin (Epo) injections and to cytotoxic agents such as 5 azacytidine 12 and hydroxyurea 6 as does ␥ chain expression of fetal hemoglobin in humans 13 and in anemic baboons.
14 Recombinant human erythropoietin (hEpo) is widely used to treat anemia which is due to chronic renal failure or other causes. 15 Recombinant hEpo also increases the proportion of HbF in patients with sickle cell disease 13 and the hemoglobin level in ␤-thalassemic patients. 16 In ␤-thalassemic mice, recombinant hEpo stimulated the ␤ minor globin gene expression, improved the hematocrit and reduced the thalassemic phenotype of erythrocytes. 7 Similar benefits were obtained from in vivo continuous recombinant mouse erythropoietin (mEpo) expression, following the Epo cDNA transduction in bone marrow cells, using a retroviral vector. 17 However, the necessary ablation of the hematopoietic stem cells of the recipient mice and the unpredictable in vivo expression of the transgene constitute major drawbacks. Fibroblasts, genetically modified to express recombinant Epo, 18 failed to improve the anemia in homozygous ␤-thalassemic mice (unpublished results).
An Epo gene transfer approach, using an encapsulated mouse myoblast line implanted subcutaneously was designed to obtain the high expression of recombinant hEpo. 19 The expression of recombinant mEpo by encapsulated myoblasts in ␤-thalassemic mice and the effects on the ␤-thalassemic phenotype are described in this study.
Results
Following the implantation of encapsulated C2C12 cells expressing approximately 14 U (140 ng) per day per capsule of mEpo, all control mice became polycythemic within 2 weeks (Figure 1a) . One mouse died from polycythemia before the end of the experiment at 12 weeks.
All ␤-thalassemic mice but one increased their hematocrit following capsule implantation (Figure 1b) . Ten of 13 responding thalassemic mice exhibited a transient increase in hematocrit that decreased to pre-implantation values within 12 weeks after implantation. Three ␤-thalassemic mice maintained high hematocrit values throughout the 12 weeks implantation period.
In control mice, the morphology of the erythrocytes was unchanged (data not shown). Conversely, in the responding Hbb thal 1 mice, the red blood cell morphology was significantly improved (Figure 2) . Most of the erythrocytes that exhibited abnormal ␤-thalassemic features before implantation had been replaced by normal looking cells 6 weeks after implantation of the capsule. In control mice the reticulocyte count increased from 2.9 to 5.6% (an absolute increase of three-to fourfold (calculated from the increase in hematocrit and in percentage of reticulocytes)), as a result of the erythropoietic stimulation induced by recombinant Epo. In ␤-thalassemic mice, the decrease in reticulocyte count from 28.5 to 10.4% (P Ͻ 0.001) and the absence of absolute increase of reticulocytes can be explained by improved erythrocyte survival overcoming the erythropoietic stimulation by recombinant Epo.
The presence of unpaired ␣ hemoglobin chains associa- ted with the erythrocyte membrane is the hallmark of the ␤-thalassemic phenotype and a more reliable marker than the ␣/␤ ratio of globin chain synthesis. In long-term responding ␤-thalassemic mice, the amount of the unpaired ␣ chains was highly reduced towards normal values from 24 to 3.4% (P = 0.002) of the total membrane proteins (Table 1) . This large decrease indicated that the most abnormal cells were replaced by erythrocytes with a reduced imbalance of ␣/␤ ratio of globin chain synthesis. In control mice, the mean serum Epo level increased from 16 ± 3.0 mU/ml to 1019 ± 764 mU/ml (P = 0.02) upon capsule implantation. In ␤-thalassemic mice, the mean Epo value increased from 192 ± 89 mU/ml to 1052 ± 2040 mU/ml after implantation, a value similar to that found in control mice (Table I ). It is noteworthy that a large variation in Epo values from 34 to 6400 mU/ml was observed among the ␤-thalassemic mice, 6 weeks after implantation. The lowest value, 34 mU/ml, was associated with a high hematocrit value (51%) and anticipated a sharp decline in the hematocrit, suggesting the loss of transgene expression or cell death. This large variation was associated with a nonsignificant difference of serum Epo before and 6 weeks after implantation of the capsules, in ␤-thalassemic mice.
All capsules were retrieved 12 weeks after implantation. The removal of the capsule was facilitated by the absence of fibrosis and adherences to the device.
For both the polycythemic control mice and the responding ␤-thalassemic mice, the ex vivo Epo secretion of the capsules explanted at the end of the study was similar to that of the same capsules before implantation. This observation demonstrated that long-term viability of C2C12 cells and stable transgene expression could be obtained in allogeneic recipients. The morphological analysis of the explanted capsules from ␤-thalassemic mice revealed clusters of living myoblasts ( Figure 3 ) with occasional multinucleated myotubes and little cell debris. Moreover, the capsules were surrounded by a thin layer of fibroblasts and a neovascular network.
In all ␤-thalassemic mice that had only a transient rise in hematocrit and in serum Epo levels, the explanted devices revealed the absence of both Epo secretion and viable myoblasts. A thin layer of fibroblastic reaction was present around the capsule, similar to that found around devices still containing viable and Epo-secreting C2C12 cells but without neo-vascularization (Figure 3 ).
Discussion
The present study demonstrates the relevance of encapsulated myoblasts transfected with an Epo-expressing vector, to produce recombinant Epo at levels high enough to improve the ␤-thalassemic phenotype in a mouse model of the human disease.
Mice were implanted subcutaneously with capsules loaded with C2C12 cells expressing the mouse Epo transgene in order to avoid immunogenicity of protein, as shown previously for the human EPO produced in mice. 20 After 12 weeks in vivo the analysis of the explanted device revealed an overall excellent viability of implanted cells in normal mice.
The presence of few multinucleated myotubes indicated that the C2C12 cells retained potential differentiation properties as previously shown. 19 The levels of hormone released at the explantation time are comparable with the pre-implantation values, confirming the long-term stability of in vivo transgene expression driven by the PGK-1 promoter in C2C12 cells and the stability of the transgene amplification conferred by the methotrexate amplification procedure. 19 The tissue reaction to the implant was mild as a result of adequate polymer biocompatibility and long-term immunoprotection.
As shown in previous studies, the explantation of the subcutaneous capsules was associated with a restoration of the baseline hematocrit within a few weeks indicating that the polycythemia was due only to the implanted device and not to cells migrating from a leaky capsule or the expression of the Epo transgene from endogeneous mouse cells. In ␤-thalassemic mice, the continuous expression of the Epo transgene increased the hematocrit value and improved the red cell phenotype and survival as suggested by the reduced proportion of reticulocyte count associated with the absence of their absolute number increase, the reduced amount of ␣ hemoglobin chains associated with the red cell membranes and the improved morphology of erythrocytes. These results are in agreement with previous studies performed with injections of recombinant hEpo for short time periods in thalassemic mice. The improvement in the hematocrit, the reduction of the ␣/␤ ratio of globin chain synthesis and a lower reticulocyte value were associated with a constant spleen size which is mostly erythropoietic in thalassemic mice.
5, 21 In these experiments, the daily dose of Epo necessary to restore the normal hematocrit in ␤-thalassemic mice was 3000 IU/kg. 21 Contrasting with control mice, long-term Epo expression was obtained only for a minority of ␤-thalassemic mice. This difference is not understood. It could be related to a reduced survival of the C2C12 cells which were implanted in thalassemic mice. These mice are anemic and iron overloaded. Major cellular activities are derived from the production of erythroid cells which is 10 times that of control mice (unpublished results) and from massive erythrophagocytosis. The removal of the large number of abnormal erythrocytes and of their precursors requires a large number of phagocytes. Changes in cytokines and hypoxia related to the anemia may be responsible for the lower frequency of encapsulated C2C12 cell survival in ␤-thalassemic mice, in contrast to the excellent survival of similar encapsulated cells in control mice. However, the increase in hematocrit 2-4 weeks after implantation of capsules in the majority of ␤-thalassemic mice 19 suggests that the initial hypoxia may not be the major stress factor for C2C12 cell survival.
Finally, the pre-implantation mean Epo levels of 192 mU/ml in ␤-thalassemic mice are a threshold value which must be overcome by the transgenic Epo expression to see an effect. Below this threshold value, the recombinant Epo will only replace the endogenous Epo production.
5 The 12-fold difference in baseline Epo levels between normal and ␤-thalassemic mice is blunted 6 weeks after implantation. Elevated hematocrit values were also observed at 12 weeks for durably responding ␤-thalassemic mice. The elevated hematocrit value reached in ␤-thalassemic mice was associated with a reduction of reticulocytes suggesting improved red cell survival upon sustained elevated levels of Epo secretion.
Several studies have shown long-term expression of recombinant Epo, following the transduction of autologous fibroblasts 18 or myoblasts 20 with retroviral vectors or direct injections of either adenoviral vectors [22] [23] [24] or adenoassociated viral vector. 25 However, until now, only ex vivo transduction of hematopoietic cells, genetically modified by a retroviral vector, has been shown to increase durably hematocrit and to improve the red cell phenotype of ␤-thalassemic mice. 17 However, the requirement for myeloablation of the recipient mice and the uncontrolled expression of transgenic Epo constitute major drawbacks to this approach.
The benefical effects of high doses of erythropoietin in human ␤-thalassemia are the increase in hematocrit in splenectomized patients with the ␤-thalassemia intermedia syndrome and the increase in HbF proportion in a minority of patients. Most probably, a higher level of erythropoietin, as obtained in the present study in mice, could better stimulate ␥ globin gene expression and increase erythrocyte survival. The mechanisms of changes due to high Epo doses in ␤-thalassemic patients as well as the stimulating effect on HbF expression in sickle cell patients and in anemic monkeys are not known.
Continuous and sustained expression of recombinant Epo by subcutaneously implanted cells in immunoprotection devices can increase the hematocrit and improve the red cell phenotype in ␤-thalassemic mice. In order to improve the proportion of ␤-thalassemic mice exhibiting long-term expression of Epo by encapsulated cells, cells are being engineered to resist cellular and metabolic stress that characterize ␤-thalassemia.
Materials and methods

Encapsulated cells
Murine C2C12 myoblasts derived from the skeletal leg muscle of an adult C3H mouse were obtained from American Type Culture Collection (ATCC: CRL 1777; Rockville, MD, USA). C2C12 myoblasts were engineered to secrete high levels of mEpo by transfection with pPImEpo-Neo-DHFR vector described previously, 18 in which hEpo cDNA was replaced by mEpo cDNA. Cells were encapsulated in microporous polyethersulfone hollow fibers (10 mm × 0.6 mm), 18, 26 and differentiated by placing the capsules in 10% Prolifix (BioMedia, Boussens, France) differentiation medium for 3 days. Each capsule was loaded with 2 × 10 5 cells. The in vitro secreted Epo was measured using an ELISA kit (R&D Systems, Minneapolis, MN, USA) before implantation in mice.
In vivo experiment Control mice (8-week-old female DBA/2J) were obtained from IFFA Credo (Orleans, France). Mice homozygous for Hbb thal 1 ␤-thalassemia have a deletion of the ␤ major gene.
2 Engineered C2C12 (mEpo) encapsulated cells were implanted subcutaneously in the dorsal flank of control or ␤-thalassemic mice. Six control mice and 14 ␤-thalassemic mice received one capsule secreting about 14 U (140 ng) mEpo per day.
Phenotype analysis Blood samples were obtained by retro-orbital sampling under general anesthesia of mice. The serum Epo concentration was measured by using an RIA commercial kit I 125 -Epo COTRIA (Biomérieux, Craponne, France). Hematocrits were measured by a standard microhematocrit method. Determination of the free ␣ globin chain in red blood cell membranes was performed by urea triton polyacrylamide gel electrophoresis (UT-PAGE) of membrane ghosts proteins. 7 Following extensive washing of membrane ghosts, the protein concentration was determined by the method of Lowry. After Coomassie Blue staining of the gel, proteins were analyzed by densitometry at 570 nm. The proportion of the membrane-associated ␣-globin chains was expressed as a percentage of membrane proteins used as reference. Reticulocytes were counted on a Coulter EPICS Profile (Coulter Electronics, Hialeah, FL, USA) after thiazole orange staining.
Statistical analysis
Hematological data are means ± standard deviation. For each group of mice, comparisons of the separate variables between the baseline (J0) and 6 weeks after implantation were performed using the two-tailed Student's t test.
